valu usd unless otherwis note
new survey inform aesthet outlook
rais target reiter op
view ran two survey gaug patient demand
medic aesthet follow lift shutdown order post-covid
well physician expect support pent-up
demand drive recoveri keep forecast cautiou
near-term increas price target move
continu see upsid
rais ep
includ continu model signific impact
improv begin investor focu
like around reflect full year contribut
progress toward billion cost synergi anticip recoveri
pandem impact busi think led
aesthet busi total revenu botox therapeut
total revenu ran two survey
look closer aesthet recoveri one focus consum demand
physician expect addit demand trend
also look updat around botox biosimilar
partnership daxi bla pdufa
view around abil meet demand exhibit physician
survey indic practic open sever takeaway
view split demand trend expect demand
next month expect ii biggest concern
regard demand appear around increas unemployment/
incom iii appear expect interest less invas
procedur surgeri could actual support trend
facial toxin filler close aesthet
iv tele-medicin expect continu physician split
whether drive effici and/or increas patient volum
patient survey result bullish around near-term
demand exhibit respond women previous
receiv facial inject last month geograph
divers ca tx fl ny/nj/ct sever takeaway
pent-up demand respond expect get
form facial inject procedur month shutdown
lift receiv treatment sinc mid-march ii
near-term plan treatment cite econom reason
incom impact cost consciou iii total
survey plan aesthet procedure/surgeri next
month plan delay procedur
time keep increas usual inject treatment appear
support point three physician survey
dissemin may produc may price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
invest thesi base view
gener double-digit near-term growth back
 catch-up strength core franchis
continu long-term question post us
humira loss exclus loe see dividend support
synergy-driven support next three year
thesi base follow key point support
see greater impact street around
expect catch-up signific
support robust growth biggest concern around
aesthet franchis compris
pro-forma revenu follow immunolog slow-down
check suggest bounc back meaning
long-term growth stori still unclear valuat
appear price littl humira goe
biosimilar see pressur out-year earn
time next year balanc sheet
focu reposit long-term growth also
see option around spin ipo acquir medic
believ highest dividend lowest
valuat could support share see upsid
potenti offens post recoveri
trade close histor low see cash flow support
current sector-high dividend help support
share anticip recoveri
atop derm
potenti catalyst sever data read focu rinvoq
skyrizi
motiv data cd induct bi voltaire-
 interchang studi read-out biosimilar humira
head-to-head calquence/imbruvica data r/r cll
risk thesi competit risk particularli around
hem-onc franchis botox slower uptak key
grower greater expect impact
bloomberg capit market estim upside/downside/target
base case see price target impli price-to-earnings
pro-forma ep
estim expect continu annual busi
strong uptak key growth product skyrizi
assum slowdown
econom downturn
upsid case scenario see valuat impli
price-to-earnings pro-forma ep
faster uptak key growth product skyrizi
lower humira eros follow us loss exclus
quicker clear relat pandem
downsid case scenario see valuat impli
price-to-earnings downsid pro-forma ep
sluggish uptak key growth product skyrizi
assum prolong deal closur allergan and/or
stringent ftc divestitur requir expect
aggress humira eros follow us loss
exclus expect
greater impact expect
survey suggest pent-up demand facial inject
survey physician dermatologist plastic surgeon view
around demand medic aesthet procedur view mix
plastic surgeon posit overal pent-up demand abil meet
demand anticip outset year factor consid
caution around patient demand given higher unemployment/great uncertainti
around incom hand physician anticip near-term trend toward non-
invas procedur facial inject shift away plastic surgeri
patient survey result larg align physician survey shift toward non-
exhibit result survey dermatologist plastic surgeon
survey believ open back within next coupl like open least anoth month practic remain open throughout anticip overal demand anticip overal demand anticip overal demand anticip overal demand anticip overal demand anticip overal demand anticip overal demand averag scoresdermpsincreas unemployment/uncertainti around incom nervou exposur go offic treatment less inclin priorit facial inject given work home/soci distanc guidelin reduc likelihood seen rel total facial inject demand anticip year believ still accommod year ie total plan /expect facial inject think get surgeon saw greater likelihood demand accomod year rel initi expect vs dermatologist consist view question pent-up overal state begin re-open much believ follow factor neg impact demand facial inject patient practic rank follow factor least import import least import trend larg similar group see increas unemploy uncertainti around incom biggest factor mute demand see short-term trend rather large-scal shift practic open back post survey physician part practic alreadi re-open post-covid open throughout and/or like open within practic open individu whose practic remain oper sinc march expect around patient demand rel period last year specif around facial inject first month state move toward derm expect demand first month re-open vs plastic surgeon derm also expect greater overal demand declin plastic surgeon anticip demand exhibit new trend anticip aris come shutdown period either patient
side term product prefer demand shift toward differ product procedur etc
dermatologistsplast surgeonsat home proceduresinterest day less invas procedur shift toward cosmet product sold websitemor demand less invas techniquespati may choos less invas treatment topic lighter peel comfort therapi less surgerychem peel microneedling decreas overheadcool sculptingattempt lower physician cost result space schedulingdemand may shift away filler continu botoxdown earthfew cosmet procedur face shield safeti protocolsi dont believ differencejust fear vovid seen chang patient desir profil across board decreas everythingmor skin care product increas use fast absorb chromic gut suturesmor surgeri less inject less emphasi cosmeticsn/aless insur option list last product major trend sharp declin recoveri previou level natur less productnon option list telemednot sure yetmor topic non-invasive proceduresnot yetn/ayesno option list im awar think persistentreduc patient volum stagger schedulingshift toward emerg case exhibit consid overal impact look forward think biggest chang
practic next month
dermatologistsplast surgeonsbudget shortfal low moral staff furloughsadapt new regulationscontinu social distanc use face masksdecreas volum continu telemedicinedown earthdecreas patient volum knowdecreas revenueincreas wait time due health precautionsemploy changeskeep schedul fullfew cosmet medic patient keep revenuefew patient due social distanc less staff new equip purchasesget back full patient load/schedul less surgeryin accommod mani patient would previous due social distanc wait roomlow overheadless cosmet lower volumeless patientsmaintain patient confid expos come officeless patient seen implement social distanc mask distancinglost revenuemor screen lower volum much less patient pt want seennonemor tele-dermatolog stringent clean procedur decreas effici practiceoffic protocol limit appt mask etcmor telehealthreduc surgic volumemor telehealthreduc surgic volumepati lose employ provid insurancerepeat shutdownspersistentschedul patientsppesoci distanc measur decreas number patient wait roomreduc patient volumespac patient ensur social distanc saniwait roomspread patient yestelemedicin becom bigger part exhibit regard util tele-medicin features/compon could drive effici potenti
increas volum within practic pleas list ye provid detail follow answer select
dermatologistsplast surgeonsy platform user friendli easi set patient endy routin followup question may handl virtual take valuabl clinic timey patient abl login ahead time ye patient time spacingy reimburs visit ye doximityy high qualiti video seamless integr emry especi video photo ye make pt seen effici even hoursy improv procedur vs clinic allocationy mani patient switch telemedicin especi simpl visit ye crisi acceler exist telemedicin trendsy platform done phoneyesy use telemedicin isotretinoin follow appointmentsno need see doyesno usey us effici telem low volum revenueno use telemedicineno didnt like telemedno would plastic surgeri visit take longer person visit almost everi situat effici may increas number consult patient would remain reluct pursu medic procedur timeno visit effici take longer offic acuiti make accur diagnos goodno increas volum concern patient due social distancingnononononononononononononebett interfac nonecommonalitynoneeas get patient log may switch use doxim work wellhonest upfrontgood resolut effici schedul better video imag qualityhigh qualiti imag user friendli weekend hour abbvi inc
patient poll women use facial inject within last
month support pent-up demand though increas cost-sensit
survey women use facial inject within last month
around view usag medic aesthet unsurprisingli cost-
sensit appear increasingli import factor though see patient
anticip limit share shift toxin
exhibit result survey women use facial inject within last month
survey year year year year year dermal recent gotten inject procedur mid-march present abl see first week stay-at-hom order first week stay-at-hom order first month stay-at-hom order near-term plan get anoth inject select follow inject receiv last month select botox frequent use facial inject facial toxin compris share last month jeuveau share facial toxin dysport xeomin select age bracketw fairli balanc mix age rang repres survey popul disclos household incom bracket soon plan get anoth inject survey reflect healthi amount pent-up demand recent receiv inject procedur anticip next procedur within month stay-at-hom order often receiv facial inject last month individu procedur count ie receiv juvederm botox one session pleas write respons inject last month frequent user exhibit result survey women use facial inject within last month continu
survey questionsresponsescommentsmi incom directli neg impact whether unemploy furlough decreas household incom directli neg impact cost-consci nervou go back provid dont see point less social/work plan delay aesthet surgeri next month increas usual use plan delay aesthet surgeri next month chang usual use plan delay aesthet surgeri next month decreas usual use plan delay aesthet plan aesthet add n/a plan facial toxin next respond select near-term plan anoth inject prior question biggest reason would delay get anoth inject procedur assum provid offic back avail respond prior question near-term plan get anoth inject procedur point heighten concern around price/ afford inject surprisingthi consist physician survey appear level mix-shift near-term away aesthet surgeri toward non-invas procedur said almost anticip chang usual use inject plan quantifi percentag total inject procedur attribut follow facial toxin next month consist indic share toxin like larg unchang surprisingli indic unlik facial toxin next month contrast indic unlik get facial inject near-term may indic increas filler usag vs select statement accur reflect view around cosmet procedur vs major aesthet surgeri ie plastic surgeri anyth invas relat aesthet next month exhibit pro-forma newco model
forma incom stand-alon modellegaci stand-alon modelless net product zenpep contributiongross profit cost synergi year oper incom expens foreign exchang incom expens interest expens incom tax tax earn ep share share per rate legaci legaci net profit analysi share per inc
price target base equal ev/ebitda price-to-earnings estim use
multipl respect reflect meaning discount histor
industri averag adjust us loss exclus humira impli return
price target support outperform rate
risk rate price target
risk rate price target includ limit tail valu risk
humira still meaning contributor combin compani acquisit risk
work integr allergan transact largest deal histori
regulatory/polit risk broadli applic sector particularli around pricing/
global biopharmaceut compani base chicago il spun
abbott becam independ publicly-trad compani compani
track record acquisit pharmacycl stemcentrx
acquisit allergan close may combin compani focus
immunolog hematolog oncolog medic aesthet neurosci franchis
